Results 121 to 130 of about 8,864 (209)

Efficacy, Safety, and Outcome Prediction of 177Lu-DOTATATE in Patients with Gastroenteropancreatic Neuroendocrine Tumours

Peptide receptor radionuclide therapy (PRRT) is indispensable in the treatment of patients with advanced, metastatic gastroeneteropancreatic neuroendocrine tumours (GEP-NETs). However, reliable predictors of response to PRRT and patient outcome are still
Mileva, Magdalena
core  

Emergency Appendectomy during the Early Phase after ¹⁷⁷Lu-DOTATATE Therapy: A Case Report with Perioperative Radiation Safety after PRRT. [PDF]

Surg Case Rep
Nakagawa K, Fukata T, Sakurai H, Yambe K, Kondo N, Takami K, Yamamoto K, Katayose Y.   +7 more
europepmc   +1 more source

SSTR2 receptor states and cellular metabolism modulate ¹⁷⁷Lu-DOTATATE binding affinity.

EANM Innov
Salomonsson SL, Engbers PAM, Nonnekens J, Bondza S.   +3 more
europepmc   +1 more source

Disseminated Intravascular Coagulation Following ¹⁷⁷Lu-Dotatate Therapy in a Patient With Metastatic Midgut Neuroendocrine Tumour: A Case Report. [PDF]

Cureus
Sharif H, McRae S.
europepmc   +1 more source

Radiation Safety Assessment of 177Lu-DOTATATE Intra-arterial Peptide Receptor Therapy (PRRT). [PDF]

Indian J Nucl Med
Chauhan MKH, Jha AK, Mithun S, Parab RD, Dwivedi P, Puranik AD, Gala KB, Shetye NS, Kulkarni S, Rangarajan V.   +9 more
europepmc   +1 more source

Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study. [PDF]

Br J Surg
Partelli S, Landoni L, Bartolomei M, Zerbi A, Grana CM, Boggi U, Butturini G, Casadei R, Salvia R, Falconi M.   +9 more
europepmc   +1 more source

Radiomics Analysis for Clinical Decision Support in 177Lu-DOTATATE Therapy of Metastatic Neuroendocrine Tumors using CT Images. [PDF]

J Biomed Phys Eng
Behmanesh B, Abdi-Saray A, Deevband MR, Amoui M, Haghighatkhah HR.   +4 more
europepmc   +1 more source

Impact of Using Corticosteroid Prophylaxis to Prevent Tumor Flare Reactions During ¹⁷⁷Lu-DOTATATE Treatment in Patients with Neuroendocrine Tumors. [PDF]

Cancers (Basel)
Cass AS, Skotte E, Wheless MC, Stockton S, Ramirez RA.   +4 more
europepmc   +1 more source

CHARACTERIZATION OF BINDING MECHANISM, INTERNALIZATION AND EXCRETION OF 177LU-DOTATATE

EANM Innovation
Hadis Westin, Sara Lundsten Salomonsson, Sina Bondza   +2 more
openaire   +1 more source

Transient bradycardia during ¹⁷⁷Lu-DOTATATE therapy: A clinically manageable phenomenon with increased risk in patients with cardiac enlargement. [PDF]

Ann Nucl Med
Yamada H, Yokoyama K, Tsuchiya J, Miura M, Katsuta E, Akahoshi K, Akiyama T, Takino K, Ban D, Tateishi U.   +9 more
europepmc   +1 more source